Related Experiment Video
Updated: May 28, 2025

Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay
Published on: September 14, 2021
Role of TGF-β/SMAD/YAP/TAZ signaling in skeletal muscle fibrosis
Felipe S Gallardo1,2, Meilyn Cruz-Soca2, Alexia Bock-Pereda2
1Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile.
Abstract:
Skeletal muscle fibrosis is strongly associated with the differentiation of its resident multipotent fibro/adipogenic progenitors (FAPs) toward the myofibroblast phenotype. Although transforming growth factor type β (TGF-β) signaling is well-known for driving FAPs differentiation and fibrosis, due to its pleiotropic functions its complete inhibition is not suitable for treating fibrotic disorders such as muscular dystrophies. Here, we describe that TGF-β operates through the mechanosensitive transcriptional regulators Yes-associated protein (YAP)/ transcriptional coactivator with PDZ-binding motif (TAZ) to determine the myofibroblast fate of FAPs and skeletal muscle fibrosis. Spatial transcriptomics analyses of dystrophic and acute injured muscles showed that areas with active fibrosis and TGF-β signaling displayed high YAP/TAZ activity. Using a TGF-β-driven fibrotic mouse model, we found that activation of YAP/TAZ in activated FAPs is associated with the fibrotic process. Mechanistically, primary culture of FAPs reveals the remarkable ability of TGF-β1 to activate YAP/TAZ through its canonical SMAD3 pathway. Moreover, inhibition of YAP/TAZ, either by disrupting its activity (with Verteporfin) or cellular mechanotransduction (with the Rho inhibitor C3 or soft matrices), decreased TGF-β1-dependent FAPs differentiation into myofibroblasts. In vivo, administration of Verteporfin in mice limits the deposition of collagen and fibronectin, and the activation of FAPs during the development of fibrosis. Overall, our work provides robust evidence for considering YAP/TAZ as a potential target in muscular fibroproliferative disorders.NEW & NOTEWORTHY The understanding of the nuclear factors governing the differentiation of muscular fibro/adipogenic progenitors (FAPs) into myofibroblasts is in its infancy. Here, we comprehensively elucidate the status, regulation, and role of the mechanotransducers Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) in the muscular fibrotic process. Our findings reveal that inhibiting cellular mechanotransduction limits FAP differentiation and the extent of muscular fibrosis exerted by transforming growth factor type β (TGF-β). This research shed new lights on the molecular mechanisms dictating the cell fate of FAPs and the muscular fibrosis.
Insights
Transforming growth factor-β (TGF-β) drives skeletal muscle fibrosis by activating Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) in fibro/adipogenic progenitors (FAPs). Inhibiting YAP/TAZ reduces FAP differentiation and fibrosis.
Area of Science:
- Cell Biology
- Musculoskeletal System Biology
- Molecular Biology
Background:
- Skeletal muscle fibrosis is linked to fibro/adipogenic progenitor (FAP) differentiation into myofibroblasts.
- Transforming growth factor-β (TGF-β) signaling promotes FAP differentiation and fibrosis, but its complete inhibition is not ideal for fibrotic disorders.
Purpose of the Study:
- To investigate the role of Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) in TGF-β-driven skeletal muscle fibrosis.
- To explore YAP/TAZ as a potential therapeutic target for muscular fibroproliferative disorders.
Main Methods:
- Spatial transcriptomics analysis of dystrophic and injured muscles.
- TGF-β-driven fibrotic mouse model and primary FAP cultures.
- Inhibition of YAP/TAZ activity and cellular mechanotransduction (Verteporfin, C3 inhibitor, soft matrices).
Main Results:
- High YAP/TAZ activity was observed in fibrotic areas with active TGF-β signaling.
- TGF-β1 activates YAP/TAZ via the SMAD3 pathway in FAPs.
- Inhibition of YAP/TAZ or mechanotransduction reduced TGF-β1-induced FAP differentiation.
- In vivo Verteporfin treatment limited fibrosis markers (collagen, fibronectin) and FAP activation.
Conclusions:
- YAP/TAZ act as key mediators of TGF-β-induced FAP differentiation and skeletal muscle fibrosis.
- Targeting YAP/TAZ or cellular mechanotransduction presents a promising therapeutic strategy for muscular fibrosis.
More Related Videos
06:33Author Spotlight: Exploring Orofacial Muscle Regeneration – Insights and Innovations
Published on: December 29, 2023
09:49Identification, Isolation, and Characterization of Fibro-Adipogenic Progenitors FAPs and Myogenic Progenitors MPs in Skeletal Muscle in the Rat
Published on: June 9, 2021
Related Concept Videos
TGF - β Signaling Pathway
The JAK-STAT Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway
Formation of Muscle Fibers from Myoblasts
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...